Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies

פריטים דומים

• Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
  מאת: Anderson, Michael S, et al.
  יצא לאור: (2017)
• Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study
  מאת: Layton, A.M., et al.
  יצא לאור: (2015)
• The role of brimonidine tartrate gel in the treatment of rosacea
  מאת: Jackson, J Mark, et al.
  יצא לאור: (2015)
• The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea
  מאת: Johnson, Andrew William, et al.
  יצא לאור: (2015)
• Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies
  מאת: Fowler, J., et al.
  יצא לאור: (2012)